How do I buy Artivion, Inc. (AORT) stock?

Buying Artivion, Inc. (AORT) stock is now easy and instant through the Gotrade app. Download the Gotrade app from the App Store or Google Play. Create an account and complete KYC. Make a deposit. Search for the code "AORT", then tap "Trade". Tap the "Buy" button. Enter the amount you want to buy. You have two options: Buy AORT by number of shares. Buy fractional shares in dollars, starting from $1. Swipe up to confirm your order, and you're done!

What is the minimum investment for AORT on Gotrade?

On Gotrade, you don't have to buy a full lot. With fractional shares, you can start investing in Artivion, Inc. from just $1. A small budget shouldn't stop you from building a US stock portfolio.

Does Artivion, Inc. (AORT) pay dividends?

At the moment, Artivion, Inc. (AORT) does not pay dividends because it focuses on reinvesting profits for company growth (a growth stock). However, you can still potentially earn profit from share price increases (capital gains). Track AORT's performance via the price chart in the Gotrade app.

Is buying AORT on Gotrade safe and legal?

Gotrade is the trading name of Gotrade Securities Inc., which is registered with and supervised by the Labuan Financial Services Authority (LFSA).

What are the market hours to buy AORT?

You can place orders 24/7. Transactions will be executed when the US market (NYSE/NASDAQ) is open, from 9:30 PM to 4:00 AM WIB. Gotrade also provides access to pre-market and after-hours trading, so you have more flexibility and aren't limited to regular working hours. Market hours may change due to daylight saving time and holidays. In Gotrade, you can see the market status (open/closed) directly in the app.

How do I tell if AORT is expensive or cheap?

There's no single perfect answer, but common approaches include: Compare valuation (e.g., P/E, P/S) against historical averages or competitors. Review revenue and earnings growth. Check margins and cash flow. Evaluate business outlook and the company's position within its industry. You can combine fundamental analysis with an investing strategy that matches your risk profile. All of the information above can be viewed directly in the Gotrade app.

Artivion, Inc. (AORT) Stock Price Today & Analysis

% positive news of 10 articles

published over the past 14 days

Latest news

MarketBeat

Endospan Announces Closing of Acquisition by Artivion, Inc., Following FDA PMA Approval of the NEXUS® Aortic Arch System

NeutralAORTMay 18, 2026

Business WireNeutral

Endospan Announces Closing of Acquisition by Artivion, Inc., Following FDA PMA Approval of the NEXUS® Aortic Arch System

AORT

MarketBeat

Artivion Q1 Earnings Call Highlights

NeutralAORTMay 9, 2026

MarketBeatNeutral

Artivion Q1 Earnings Call Highlights

AORT

Zacks Investment Research

Artivion (AORT) Q1 Earnings and Revenues Surpass Estimates

NeutralAORTMay 8, 2026

Zacks Investment ResearchNeutral

Artivion (AORT) Q1 Earnings and Revenues Surpass Estimates

AORT

Zacks Investment Research

Artivion Secures FDA Approval for NEXUS Aortic Arch System

NeutralAORTApril 8, 2026

Zacks Investment ResearchNeutral

Artivion Secures FDA Approval for NEXUS Aortic Arch System

AORT

Zacks Investment Research

Artivion (AORT) Soars 5.3%: Is Further Upside Left in the Stock?

NeutralAORTApril 8, 2026

Zacks Investment ResearchNeutral

Artivion (AORT) Soars 5.3%: Is Further Upside Left in the Stock?

AORT

Zacks Investment Research

Artivion (AORT) Q4 Earnings Surpass Estimates

NeutralAORTFebruary 12, 2026

Zacks Investment ResearchNeutral

Artivion (AORT) Q4 Earnings Surpass Estimates

AORT

InvestorPlace

3 Earnings All-Stars With More Room to Run

NeutralAORTJuly 3, 2024

InvestorPlaceNeutral

3 Earnings All-Stars With More Room to Run

AORT

About Artivion, Inc.

Artivion Inc offers cardiac and vascular surgeons a suite of aortic-centric solutions. The company's products include Aortic Heart Valve, Mitral Heart Valve, Aortic Allograft, Pulmonary Human Heart Valve, Pulmonary Patch, and Surgical Adhesive among others. The company's has two reportable segments: Medical Devices and Preservation Services. The Medical Devices segment includes revenues from sales of aortic stent grafts, surgical sealants, On-X products, and other product revenues. The Preservation Services segment includes services revenues from the preservation of cardiac and vascular implantable human tissues. Company operates in North America, EMEA. LATAM, APAC. Maximum revenue is from North America.

SectorHealthcare

IndustryMedical Devices

Employees1,800

CEOMr. James Patrick Mackin

IPO DateFeb 12, 1993

HeadquartersKennesaw, GA

Key Executives

Name	Title	Year Born
Mr. James Patrick Mackin	Chairman, President & CEO	1967
Mr. Lance A. Berry CPA	EVP, COO, CFO & Treasurer	1972
Ms. Jean F. Holloway Esq.	Senior VP, General Counsel, Chief Compliance Officer & Corporate Secretary	1957
Mr. John E. Davis	Senior VP & Chief Commercial Officer	1965
Ms. Amy D. Horton CPA	VP & Chief Accounting Officer	1970
Mr. Matthew A. Getz	VP of Human Resources & Chief Human Resources Officer	1969
Mr. Jason D. Asper	Senior VP and Chief Strategy & Digital Officer	1976
Mr. Andrew M. Green	Senior Vice President of Regulatory & Quality	1969
Dr. Simona Zannetti M.D.	Senior Vice President of Clinical Research & Chief Medical Officer	—
Dr. Robert C. Thomson Ph.D.	Vice President of Research & Development	1971

Fundamentals

Valuation

Market cap$1.10B

Price-to-sales ratio2.38

Price-to-book value2.52

Price-earnings ratio-354.80

Return on Equity3.00%

Return on Sales9.00%

Return on Assets1.00%

PEG ratio181.50

Earnings Per Share

Earnings Per Share$-0.05

Income Statement

Average volume653,785

EBITDA$70.29M

1 year high (52w)$48.25

1 year low (52w)$19.16

Dividend

Ex dividend date9 Dec 2015

Dividend amount$0.00

Dividend yield0.00%

Last payment dateN/A

Dividend yield (TTM)N/A

Next earnings reportN/A

Solvency

Debt-to-equity ratioN/A

Technicals

OscillatorsSell5 Indicators

Moving AveragesStrong Sell12 Indicators

What the experts say

2 Wall Street Analyst Ratings

BUY

100% Buy

0% Hold

0% Sell

Target price

$42.00

Est return

84.62%

Canaccord Genuity

William Plovanic

Buy

Target price

$40.00

Est return

75.82%

Needham

Mike Matson

Buy

Target price

$44.00

Est return

93.41%

Seasonality

Monthly price change (%)

	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
2026		+8.9	-5.0	+4.9	-38.7	+6.7	+13.9	-1.7	-16.5

Artivion, Inc. (AORT) Stock

Fundamentals

Recent news

Artivion Q2 Earnings Call Highlights

Artivion Q2 Earnings Call Highlights

Artivion (AORT) Q2 Earnings Meet Estimates

Artivion (AORT) Q2 Earnings Meet Estimates

Artivion Secures FDA Approval for AMDS Hybrid Prosthesis Device

Artivion Secures FDA Approval for AMDS Hybrid Prosthesis Device

Endospan Announces Closing of Acquisition by Artivion, Inc., Following FDA PMA Approval of the NEXUS® Aortic Arch System

Endospan Announces Closing of Acquisition by Artivion, Inc., Following FDA PMA Approval of the NEXUS® Aortic Arch System

Technicals

Analyst Ratings

Financials

Performance

Debt & Balance Sheet

Revenue to Profit

Earnings

Latest news

Artivion Q2 Earnings Call Highlights

Artivion Q2 Earnings Call Highlights

Artivion (AORT) Q2 Earnings Meet Estimates

Artivion (AORT) Q2 Earnings Meet Estimates

Artivion Secures FDA Approval for AMDS Hybrid Prosthesis Device

Artivion Secures FDA Approval for AMDS Hybrid Prosthesis Device

Endospan Announces Closing of Acquisition by Artivion, Inc., Following FDA PMA Approval of the NEXUS® Aortic Arch System

Endospan Announces Closing of Acquisition by Artivion, Inc., Following FDA PMA Approval of the NEXUS® Aortic Arch System

Artivion Q1 Earnings Call Highlights

Artivion Q1 Earnings Call Highlights

Artivion (AORT) Q1 Earnings and Revenues Surpass Estimates

Artivion (AORT) Q1 Earnings and Revenues Surpass Estimates

Artivion Secures FDA Approval for NEXUS Aortic Arch System

Artivion Secures FDA Approval for NEXUS Aortic Arch System

Artivion (AORT) Soars 5.3%: Is Further Upside Left in the Stock?

Artivion (AORT) Soars 5.3%: Is Further Upside Left in the Stock?

Artivion (AORT) Q4 Earnings Surpass Estimates

Artivion (AORT) Q4 Earnings Surpass Estimates

3 Earnings All-Stars With More Room to Run

3 Earnings All-Stars With More Room to Run

About Artivion, Inc.

Key Executives

Fundamentals

Valuation

Earnings Per Share

Income Statement

Dividend

Solvency

Technicals

What the experts say

Seasonality

FAQ

Trading Lebih Cepat. Lebih Mudah. Lebih Cerdas.

#ReadyGoTrade